MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares traded down 0.4% during mid-day trading on Wednesday . The stock traded as low as $2.50 and last traded at $2.51. 7,858 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 169,116 shares. The stock had previously closed at $2.52.
MiNK Therapeutics Price Performance
The company's 50-day moving average is $2.35 and its 200-day moving average is $2.02.
Get MiNK Therapeutics alerts:MiNK Therapeutics (NASDAQ:INKT – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.04. Analysts anticipate that MiNK Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On MiNK Therapeutics
An institutional investor recently bought a new position in MiNK Therapeutics stock. First Republic Investment Management Inc. acquired a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 81,500 shares of the company's stock, valued at approximately $172,000. First Republic Investment Management Inc. owned approximately 0.24% of MiNK Therapeutics at the end of the most recent reporting period. Institutional investors own 1.07% of the company's stock.MiNK Therapeutics Company Profile
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Featured Articles
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- This Is Why Daktronics Fell 40% In One Day
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.